RU2002115406A - Compound possessing the properties of the release of growth hormone - Google Patents

Compound possessing the properties of the release of growth hormone

Info

Publication number
RU2002115406A
RU2002115406A RU2002115406/04A RU2002115406A RU2002115406A RU 2002115406 A RU2002115406 A RU 2002115406A RU 2002115406/04 A RU2002115406/04 A RU 2002115406/04A RU 2002115406 A RU2002115406 A RU 2002115406A RU 2002115406 A RU2002115406 A RU 2002115406A
Authority
RU
Russia
Prior art keywords
release
pharmaceutical composition
growth hormone
compound according
composition according
Prior art date
Application number
RU2002115406/04A
Other languages
Russian (ru)
Other versions
RU2272034C2 (en
Inventor
Микаэль АНКЕРСЕН
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Priority claimed from PCT/DK2000/000624 external-priority patent/WO2001034593A1/en
Publication of RU2002115406A publication Critical patent/RU2002115406A/en
Application granted granted Critical
Publication of RU2272034C2 publication Critical patent/RU2272034C2/en

Links

Claims (8)

1. 2-амино-N-[(1R)-2-[(3R)-3-бензил-3-(N,N’,N’-триметил-гидразинокарбонил)пиперидин-1-ил]-1-(lH-индол-3-илметил)-2-оксоэтил]-2-метилпропионамид1.2-amino-N - [(1R) -2 - [(3R) -3-benzyl-3- (N, N ', N'-trimethyl-hydrazinocarbonyl) piperidin-1-yl] -1- (lH -indol-3-ylmethyl) -2-oxoethyl] -2-methylpropionamide
Figure 00000001
Figure 00000001
 или его фармацевтически приемлемая соль.or a pharmaceutically acceptable salt thereof. 2. Фармацевтическая композиция, включающая в качестве активного ингредиента соединение по п.1 вместе с фармацевтически приемлемым носителем или разбавителем.2. A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent. 3. Фармацевтическая композиция по п.2 для стимулирования высвобождения гормона роста из гипофиза.3. The pharmaceutical composition according to claim 2 for stimulating the release of growth hormone from the pituitary gland. 4. Фармацевтическая композиция по п.2 или 3 для введения животным для повышения скорости и степени роста, увеличения производства молока или шерсти или лечения недомоганий.4. The pharmaceutical composition according to claim 2 or 3 for administration to animals to increase the speed and degree of growth, increase the production of milk or wool or treat ailments. 5. Способ стимулирования высвобождения гормона роста из гипофиза млекопитающего, включающий введение указанному млекопитающему эффективного количества соединения по п.1 или фармацевтической композиции по любому из пп.2-4.5. A method of stimulating the release of growth hormone from the pituitary of a mammal, comprising administering to said mammal an effective amount of a compound according to claim 1 or a pharmaceutical composition according to any one of claims 2-4. 6. Способ повышения скорости и степени роста, увеличения производства молока или шерсти или лечения недомоганий, включающий введение нуждающемуся в этом животному эффективного количества соединения по п.1 или фармацевтической композиции по любому из пп.2-4.6. A method of increasing the speed and degree of growth, increasing milk or wool production or treating ailments, comprising administering to an animal in need thereof an effective amount of a compound according to claim 1 or a pharmaceutical composition according to any one of claims 2-4. 7. Применение соединения по п.1 или его фармацевтически приемлемой соли для получения лекарственного средства.7. The use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament. 8. Применение по п.7 для получения лекарственного средства для стимулирования высвобождения гормона роста из гипофиза млекопитающего.8. The use according to claim 7 for the manufacture of a medicament for stimulating the release of growth hormone from the pituitary of a mammal.
RU2002115406/04A 1999-11-10 2000-11-10 2-amino-n-{(1r)-2-[(3r)-3-benzyl-3-(n,n',n'-trimethylhydrazinocarbonyl)piperidine-1-yl]-1-(1h-indol-3-ylmethyl)-2-oxoethyl}-2-methylpropionamide or its pharmaceutically acceptable salt, pharmaceutical composition based on thereof and method for stimulation of growth hormone release from mammal hypophysis RU2272034C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901618 1999-11-10
DKPA199901618 1999-11-10
US16710199P 1999-11-23 1999-11-23
PCT/DK2000/000624 WO2001034593A1 (en) 1999-11-10 2000-11-10 Compound with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
RU2002115406A true RU2002115406A (en) 2003-12-27
RU2272034C2 RU2272034C2 (en) 2006-03-20

Family

ID=26065963

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002115406/04A RU2272034C2 (en) 1999-11-10 2000-11-10 2-amino-n-{(1r)-2-[(3r)-3-benzyl-3-(n,n',n'-trimethylhydrazinocarbonyl)piperidine-1-yl]-1-(1h-indol-3-ylmethyl)-2-oxoethyl}-2-methylpropionamide or its pharmaceutically acceptable salt, pharmaceutical composition based on thereof and method for stimulation of growth hormone release from mammal hypophysis

Country Status (23)

Country Link
US (1) US6576648B2 (en)
EP (1) EP1230236B1 (en)
JP (2) JP2003527338A (en)
KR (1) KR100907637B1 (en)
CN (1) CN1198818C (en)
AT (1) ATE280168T1 (en)
AU (1) AU782260B2 (en)
BR (1) BR0015407A (en)
CA (1) CA2387095C (en)
CZ (1) CZ301078B6 (en)
DE (1) DE60015173T2 (en)
DK (1) DK1230236T3 (en)
ES (1) ES2231279T3 (en)
HU (1) HU229445B1 (en)
IL (1) IL149049A0 (en)
MX (1) MXPA02004656A (en)
NO (1) NO323910B1 (en)
PL (1) PL199989B1 (en)
PT (1) PT1230236E (en)
RU (1) RU2272034C2 (en)
UA (1) UA73530C2 (en)
WO (1) WO2001034593A1 (en)
ZA (1) ZA200202757B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531769A (en) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド Method for reducing C-reactive protein using growth hormone secretagogue
EP1768976B1 (en) 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
AU2005272074B2 (en) * 2004-06-29 2011-11-24 Albany Molecular Research, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
KR20090042779A (en) * 2006-06-30 2009-04-30 쉐링 코포레이션 Substituted piperidines that increase p53 activity and the uses thereof
WO2008100448A2 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (en) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc Methods of treating or preventing emesis using growth hormone secretagogues
US8664267B2 (en) * 2007-04-12 2014-03-04 Academic Pharmaceuticals Incorporated Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide)
RU2482117C2 (en) 2008-02-08 2013-05-20 Зериа Фармасьютикал Ко., Лтд. 3,8-diaminotetrahydroquinoline derivative
UA105657C2 (en) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Enhanced migraine treatments based on anamorelin
JO3353B1 (en) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co Isolated solid form of anamorelin monohydrochloride with low molar ratio of chloride : anamolerin and low content of residual organic solvent
IN2015DN04172A (en) 2012-10-24 2015-10-16 Daiichi Sankyo Companyltd
WO2017067438A1 (en) * 2015-10-20 2017-04-27 江苏恒瑞医药股份有限公司 Crystal form of anamorelin and preparation method therefor
CN106187865A (en) * 2016-07-08 2016-12-07 武汉工程大学 (R) synthesis of 1 tertbutyloxycarbonyl 3 benzyl 3 carboxylic acid piperidin and chiral separation method
CN108129357B (en) * 2016-12-01 2021-12-21 上海医药工业研究院 Preparation method of anamorelin intermediate
CN108239141A (en) * 2016-12-23 2018-07-03 江苏先声药业有限公司 A kind of preparation method of anamorelin
US20220323430A1 (en) * 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
CN114805305B (en) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 Compound and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
EP0400051B1 (en) 1988-01-28 1995-05-10 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
EP0417165B1 (en) 1988-05-11 1994-01-26 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IT1240643B (en) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
HUT74733A (en) * 1993-11-09 1997-02-28 Merck & Co Inc Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JPH09505601A (en) 1993-11-24 1997-06-03 メルク エンド カンパニー インコーポレーテッド Indolyl-containing compounds and their use to promote growth hormone release
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5922770A (en) * 1996-07-22 1999-07-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU766305B2 (en) * 1998-01-16 2003-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE69941255D1 (en) * 1998-05-11 2009-09-24 Novo Nordisk As CONNECTIONS WITH GROWTH HORMONE RELEASING PROPERTIES
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake

Similar Documents

Publication Publication Date Title
RU2002115406A (en) Compound possessing the properties of the release of growth hormone
CA2387095A1 (en) Compound with growth hormone releasing properties
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
EA200601799A1 (en) HYDRAZIDE-CONTAINING COMPOUNDS - CFTR INHIBITORS AND THEIR APPLICATION
ATE375341T1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OR PREVENTION OF PAIN
JP2010524915A (en) Progesterone antagonists and selective progesterone modulators in the treatment of excessive uterine bleeding
JP2005502643A5 (en)
JP2019517578A (en) Compositions and methods of using nintedanib to treat eye diseases associated with abnormal neovascularization
JP2003517014A (en) Pharmaceutical implant containing immediate release and sustained release components and administration method
EP1317419A4 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2005115345A1 (en) Oral therapeutic compound delivery system
JP2008518916A (en) Composition for controlled delivery of pharmaceutically active compounds
JP2006514092A5 (en)
KR930003915A (en) Medications for rejection response to organ transplantation
BG108339A (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
CN108325054A (en) Alimentary infection intracavitary therapy system
ATE282406T1 (en) MEDICINAL PRODUCTS AND METHODS FOR THE TREATMENT OF INTRACELLULAR INFECTIONS
RU2002122084A (en) COMBINATION OF MEDICINES, INCLUDING MIRTAZAPINE, FOR THE TREATMENT OF DEPRESSION AND RELATED DISORDERS
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
JP2000507234A (en) Intranasal administration of treatment for delayed onset vomiting
RU2005135649A (en) COMBINATIONS OF PAROXETIN AND 4- (S) - (4-ACETYLPIPERAZIN-1-IL) -2- (R) - (4-fluoro-2-methylphenyl) piperidine-1-carboxylic acid [1- (R) - (3, 5-BIS-TRIFFORMETHYLPHENYL) ETHYL] METHYLAMIDE FOR THE TREATMENT OF DEPRESSION AND / OR ALARM
US20210386736A1 (en) Combination therapy for treating cancer
JP2005538052A (en) Injection formulation
WO2019008472A1 (en) Pharmaceutical compositions of lignocaine hcl
US11033545B2 (en) Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages